Drugs / DHES0815A
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03451162 | Apr 2018 → Jul 2021 | breast cancer | Genentech, Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DHES0815A | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03451162 ↗ |
| Route | Intravenous | “DHES0815A will be administered via intravenous (IV) infusion on Day 1 of each 21-day cycle.” NCT03451162 ↗ |